ICAM1 and myeloid sarcoma: Considering that the conclusions we can draw are still speculative, it is mandatory, to further explore which patients may specifically benefit from EID of NTZ, further studies will be needed, including exploring the options for determining expression levels of ICAM-1 and VCAM-1 on the BBB in MS patients.